Improving clinical trials
We believe clinical trials can work better, so we're bringing the right people together to make trials faster, cheaper and more likely to succeed.
Slice title
The Critical Path for Parkinson's
Our Director of Research, Dr Arthur Roach, explains more about this exciting and essential initiative.
Clinical trials are the most costly and lengthy part of the whole research process. In recent years, several promising new treatments for Parkinson's have failed to show benefit in clinical trials.
Many in the research community believe the problem may not be that the drugs don't work, but that we're testing them in the wrong way.
That's why we fund and lead the Critical Path for Parkinson's.
This international collaboration brings together pharmaceutical companies, regulatory agencies, universities and charities to share data from major studies and trials.
Our expert partner - the Critical Path Institute - is using this data to develop new tools and strategies to improve clinical trials for Parkinson's.
Meet our expert partners: Critical Path Institute
Critical Path Institute is an independent non-profit dedicated to bringing scientists together to collaborate and improve the drug development process.
Some of the world’s largest pharmaceutical companies have joined our groundbreaking initiative to improve clinical trials for Parkinson's.
The Critical Path for Parkinson's has delivered a new tool in the search for new Parkinson's treatments - a brain scan that can be used to select the right people for clinical trials.
Our ambitious collaboration aims to change the way clinical trials are carried out, and help ensure new treatments reach people with Parkinson's faster.
ABOUT OUR RESEARCH
Everything we do is driven by people affected by Parkinson's. That's why we're striving for new and better treatments - in years, not decades.
Find out how we're speeding up Parkinson's research and how you can get involved.